AI Tool Forecasts Diabetes Complications
New AI tool forecasts diabetes complications in patients, helping prevent heart disease and kidney disease risks.
FDA clears new drug for rare skin condition
The FDA approved Lisraya (brepocitinib) for dermatomyositis, a rare skin condition causing inflammation and muscle weakness, offering targeted treatment.
FDA approves first-of-its-kind therapy for metastatic pancreatic cancer
FDA approves Rasonque, a first-in-class therapy for metastatic pancreatic cancer. Learn about this new targeted treatment.
Stem cell donors getting younger and better
Stem cell donors are getting younger and better, with mismatched unrelated donors showing promising survival rates for adults with blood…
Anti-inflammatories emerge as new seborrheic dermatitis treatment
Discover why dermatologists are shifting toward anti-inflammatory seborrheic dermatitis treatment to improve patient outcomes and reduce drug resistance.
FDA approves new drug for rare bone disease
The FDA approves Pasatru, a breakthrough drug for fibrodysplasia ossificans progressiva (FOP), a rare bone disease affecting 900 people worldwide.
Sparsentan Access Guidance for Kidney Disease Patients
Sparsentan access guidance for kidney disease patients with evidence-based coverage criteria and clinical judgment.
Scientists Identify New Pathway to Combat Liver Inflammation
Researchers find hormone GDF15 triggers a brain‑to‑liver pathway that cuts liver inflammation and fibrosis, offering therapy even without weight loss.
Clinical Trial Joining: The Hurdles You Need to Know
Discover the hurdles of clinical trial joining and how to overcome them with ease and success in medical research and…
California’s generic insulin struggles to gain traction
California’s generic insulin program, CalRx, offers affordable insulin at $55 but faces slow adoption despite lower costs. Learn why.